Low‐dose basiliximab induction therapy in heart transplantation

Veraprapas Kittipibul; Pakpoom Tantrachoti; Pat Ongcharit; Aekarach Ariyachaipanich; Sarawut Siwamogsatham; Supaporn Sritangsirikul; Kanokwan Thammanatsakul; Sarinya Puwanant

doi:10.1111/ctr.13132

journal article Nov 03, 2017

Low‐dose basiliximab induction therapy in heart transplantation

Veraprapas Kittipibul Pakpoom Tantrachoti Pat Ongcharit Aekarach Ariyachaipanich Sarawut Siwamogsatham Supaporn Sritangsirikul Kanokwan Thammanatsakul Sarinya Puwanant

Clinical Transplantation Vol. 31 No. 12 · Wiley

View at Publisher Save 10.1111/ctr.13132

Abstract

AbstractWe prospectively studied efficacy and safety outcomes of two 10‐mg doses of intravenous basiliximab on day 0 and day 4 for induction therapy in 17 consecutive de novo heart transplant recipients. By the 2‐week assessment post‐transplant, there were no deaths, graft failures, or acute cellular rejections (ACRs) ISHLT grade ≥ 2R. By the 1‐year assessment post‐transplant, there were 1 (6%) infectious death, no graft failures, 2 (12%) grade 2R ACRs, 6 (35%) asymptomatic cytomegalovirus (CMV) infections, and 4 (25%) treated infections. Our study was the first to show that low‐dose basiliximab induction in heart transplant resulted in favorable efficacy and safety outcomes. Additionally, calcineurin inhibitor (CNI) initiation in a low‐risk population could be safely delayed using the strategy of modified low‐dose postoperative basiliximab. This strategy also appears to allow subsequent early corticosteroid wean, although with the concomitant maintenance of higher CNI levels and higher dosing of mycophenolate.

Topics

No keywords indexed for this article. Browse by subject →

References

10

[1]

10.1093/ndt/16.9.1756

[2]

10.1016/j.healun.2016.08.017

[3]

10.1111/j.1432-2277.1996.tb01641.x

[4]

10.1097/00007890-199712270-00012

[5]

10.1097/00007890-200210150-00011

[6]

10.1097/00007890-199510150-00023

[7]

10.1016/j.healun.2004.09.010

[8]

10.1016/j.healun.2007.01.006

[9]

10.1016/j.healun.2007.05.002

[10]

10.1097/01.tp.0000209924.00229.e5

Metrics

16

Citations

10

References

Details

Published: Nov 03, 2017
Vol/Issue: 31(12)
License: View

Authors

V

Veraprapas Kittipibul

Division of Cardiovascular Medicine Department of Medicine Faculty of Medicine Chulalongkorn University Bangkok Thailand

P

Pakpoom Tantrachoti

Division of Cardiovascular Medicine Department of Medicine Faculty of Medicine Chulalongkorn University Bangkok Thailand

P

Pat Ongcharit

Cardiac Center King Chulalongkorn Memorial Hospital Thai Red Cross Society Bangkok Thailand

A

Aekarach Ariyachaipanich

Division of Cardiovascular Medicine Department of Medicine Faculty of Medicine Chulalongkorn University Bangkok Thailand; Excellent Center of Organ Transplantation King Chulalongkorn Memorial Hospital Thai Red Cross Society Bangkok Thailand

S

Sarawut Siwamogsatham

Division of Cardiovascular Medicine Department of Medicine Faculty of Medicine Chulalongkorn University Bangkok Thailand; Cardiac Center King Chulalongkorn Memorial Hospital Thai Red Cross Society Bangkok Thailand

S

Supaporn Sritangsirikul

Excellent Center of Organ Transplantation King Chulalongkorn Memorial Hospital Thai Red Cross Society Bangkok Thailand

K

Kanokwan Thammanatsakul

Excellent Center of Organ Transplantation King Chulalongkorn Memorial Hospital Thai Red Cross Society Bangkok Thailand

S

Sarinya Puwanant

Division of Cardiovascular Medicine Department of Medicine Faculty of Medicine Chulalongkorn University Bangkok Thailand; Cardiac Center King Chulalongkorn Memorial Hospital Thai Red Cross Society Bangkok Thailand

Cite This Article

Veraprapas Kittipibul, Pakpoom Tantrachoti, Pat Ongcharit, et al. (2017). Low‐dose basiliximab induction therapy in heart transplantation. Clinical Transplantation, 31(12). https://doi.org/10.1111/ctr.13132

Low‐dose basiliximab induction therapy in heart transplantation

You May Also Like